AzTrials
AzTrials

Cirrhosis, LiverNCT05346029

Role of Sarcopenia and Nutritional/Physical Therapy Intervention in Post-TIPS Hepatic Encephalopathy

A study testing Lifestyle intervention in people with Cirrhosis, Liver and Hepatic Encephalopathy, run by Anna Baiges at 3 sites in Spain.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

The placement of TIPS (transjugular intrahepatic portosystemic shunt) is the most effective strategy to treat complications of portal hypertension. However, the threat of developing post-TIPS complications diminishes its use and applicability. Read more about this study

Who is it for?
Ages 18 years and older
What is being tested?
Lifestyle intervention
Could I receive a placebo?
No, everyone receives an active treatment
How many people
140 participants
Where
3 sitesSpain
Study dates
1 Jan 2022to 31 Dec 2025
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • All cirrhotic patients submitted for elective TIPS

Who cannot join

  • Contraindication for TIPS placement, contraindication for physical therapy

Trial locations and contacts

3 sites in 1 country.

Anna Baiges, MD, PhD contact

93 227 54 00 ext. 2824

abaigesa@clinic.cat

Joan Carles García Pagan, MD, PhD contact

93 227 54 00 ext. 5790

jcgarcia@clinic.cat

Spain3 sites, 3 recruiting
  • Hospital Clínic de Barcelona

    Barcelona, Catalonia, 08036

    Anna Baiges

    Recruiting
  • Hospital Universitario Gregorio Marañón

    Madrid

    Luis Ibáñez-Samaniego

    Recruiting
  • Hospital Universitario Ramon y Cajal

    Madrid

    Luis Tellez, MD, PhD

    Recruiting

Other trials in Spain

About this study

Official title: Expanding the Therapeutic Landscape of Post-TIPS Hepatic Encephalopathy

The placement of TIPS (transjugular intrahepatic portosystemic shunt) is the most effective strategy to treat complications of portal hypertension. However, the threat of developing post-TIPS complications diminishes its use and applicability. Hepatic encephalopathy (HE) is the most feared and frequent post-TIPS complication, affecting between 25-54% of patients. Available treatments against HE are only partially effective. Therefore, the best existing strategy is to accurately select patients for TIPS excluding those presenting known high risk factors associated to post-TIPS HE. Despite applying this approach, the incidence of post-TIPS HE still remains very high. The investigators hypothesize that a better identification of risk factors for post-TIPS HE, together with the introduction of therapeutic interventions modulating pathophysiological mechanisms involved in post-TIPS HE development - among which sarcopenia stands out- would lead to a reduction in the incidence of HE and, eventually, to an increase in the number of patients benefiting from TIPS.

Thus, our project is aimed at

  1. Demonstrate that a 12 weeks lifestyle intervention based on resistance training and nutritional counseling can reduce sarcopenia and, ultimately, post-TIPS HE.
  2. To study predictive factors of post-TIPS HE, focusing on the role of factors that have never been evaluated in the setting of TIPS: gut microbiome and cognitive function
Read the detailed description

1.- To evaluate the impact of a 12 weeks lifestyle intervention aimed to reduce sarcopenia in post-TIPS hepatic encephalopathy development

The first aim of the study will be approached by an open-label multicenter two arms randomized clinical trial, conducted in Hospital Clínic de Barcelona, Hospital Universitario Ramón y Cajal and Hospital Gregorio Marañón.

All cirrhotic patients submitted for elective TIPS in any of these three hospitals will be eligible. Patients fulfilling inclusion criteria and willing to participate will provide written informed consent and will be randomized to intervention or observational group in a 1:1 ratio. The randomization sequence will be generated by computer. The coded treatment assignment will be kept at the coordinating center in sealed, consecutively numbered, opaque envelopes.

All TIPS procedures will be carried out using PFTE-covered stents and using a stepwise dilatation ideally aiming at a final GPP between 10 and 12 mmHg (below 12 mmHg to protect from portal hypertension, over 10 mmHg to avoid post-TIPS HE).

Follow-up visits will be scheduled at 4 weeks, 12 weeks and 6 months post-TIPS. Patients will be followed up until death, liver transplantation or 6 months after TIPS placement.

Primary outcome: development of post-TIPS overt HE within 6 months after TIPS placement. Overt HE will be defined if any grade from 2 to 4 of West Haven Criteria are present: grade 2, fatigue, apathy, flapping tremor, ataxia, slurred speech; grade 3, somnolence, marked disorientation, rigor, stupor; grade 4, coma.

Secondary outcome: 6 months mortality; development of a second episode of overt HE within the first 6 month; development of minimal HE within the first 6 months; time to development of either overt or minimal HE; development of portal complications during follow-up; effects on sarcopenia; need of admission; percentage of follow-up days spent in the hospital.

Sample size The incidence of post-TIPS HE is stablished at 45% . It is assumed that the effects of a lifestyle intervention comprising resistance training and nutritional counseling could achieve a 50% reduction of HE. With a two-sided 5% alpha and power of 80%, a total of 70 study subjects are needed in each group. A total number of 140 patients is a realistic and achievable enrollment in our clinical setting.

Study subjects The study will include patients with clinical, histological or radiological criteria of cirrhosis that need to be treated with an elective TIPS. Exclusion criteria will be pulmonary hypertension, hepatocelular carcinoma out of Milan criteria, severe liver failure or clinical heart failure and impossibility to perform resistance training. Circumstances directly influencing microbiome (use of antibiotics, lactulose, proton pump inhibitors) will be accurately recorded but will not be considered an exclusion criteria in order to truthfully reflect the usual scenario of clinical practice.

Variables to be collected at baseline, 4 weeks and 6 months The tests contained in the protocol are non-invasive. Clinical follow-up does not differ from the usual for any patient undergoing TIPS.

Blood test Fasting venous blood will be analyzed for liver function tests and ammonia, blood count, general biochemistry and coagulation parameters.

Clinical data including cirrhosis etiology, stage of liver disease, renal function and comorbidities.

Sarcopenia assessment: Sarcopenia will be assessed by: measurement of transversal psoas muscle thickness at CT scan, Liver Frailty Index and muscle strength evaluation (maximal isokinetic strength of the knee extensors).

Transversal psoas muscle thickness normalized per height (TPMT, mm/m) will be assessed in CT scans at baseline (taking advantage of CT scan routinely performed before TIPS to evaluate the splanchnic veins and detect possible technical complications) and 6 months post-TIPS. Measurement of transversal psoas muscle thickness has been shown to be an effective tool to objectively evaluate sarcopenia and predict prognosis in cirrhotic patients, with better accuracy than alternatives such as total cross-sectional area of abdominal skeletal muscle and with the clear advantage of being technically easier.

Liver Frailty Index (LFI) Liver Frailty Index has been evaluated in patients with cirrhosis and has been shown to predict mortality in the LT waiting list.

Muscle strength evaluation. Maximal isokinetic strength of the knee extensors will be determined on the non-dominant leg at a velocity of 90º/s. Eight repetitions will be recorded, each test separated by a 15 second rest. The maximal measured torque will be used in all analyses.

Lifestyle Intervention: Resistance training and nutritional counseling vs standard of care (SOC). Data regarding whether patients already perform exercise and which kind, intensity and duration will be collected at baseline through the International Physical Activity Questionnaire. Patients in the intervention group will begin a resistance training program + nutritional counseling. The investigators have set the intervention duration at twelve weeks because it has been proved that a 12 weeks of resistance training increases muscle strength and muscle size in cirrhosis. Sixty minutes sessions (10 minutes of warmup, 40 minutes of limbs and arms strength exercising routine and 10 minutes of cooling down) will be conducted three non-consecutive days per week and will be supervised by a professional physiotherapist. Exercise intensity will be increased and monitored through the Borg subjective Perception of Exertion Scale. The three participating hospitals are referral centers for portal hypertension complications. Some of the patients treated in these hospitals might not live in the same city and might not be able to presentially attend our facilities 3 days per week. To overcome this possible limitation, the physical training plan has been adapted so that two sessions per week will be telematically supervised.

A nutritional status assessment will be carried out, assessing the diagnosis of malnutrition using the GLIM (Global Leadership Initiative on Malnutrition) criteria. The nutritional intervention will be individualized and advised by a dietitian-nutritionist. Nutritional counseling will be aimed at ensuring the required energy and protein intake through dietary enrichment and late evening snacks. In general terms, it will be recommended to aim for an energy intake of 30-35 kcal/kg/day to maintain body weight at times of major stress, and a daily intake of 1.2 - 1.5 g of protein/kg/day to achieve anabolism. Supplementation using a whey protein module will be indicated with the aim to stimulate muscle mass synthesis. Dietary protein intake will be equally distributed in 3 main meals ensuring a minimum of 20-30g protein/meal, and the optimal time for protein supplementation (0.4g/kg) will be indicated after physical training (3 times/week).

Patients included in the SOC will have the same baseline evaluation and follow-up scheduled visits but without performing resistance training and nutritional counseling.

Second aim: identification of more accurate predictive factors of post-TIPS hepatic encephalopathy that will consequently optimize the use of TIPS and open potential future lines of intervention All the baseline data collected for the first aim will be included in the assessment of post-TIPS HE. Furthermore, microbiome analysis and neuropsychological evaluation will be performed.

  • Microbiome analysis. Gut microbiome will be analyzed at baseline and 4 weeks post-TIPS. All the samples from the three hospitals will be processed in Hospital Clínic de Barcelona. Fecal samples collection. Fecal samples will be collected following the International Human Microbiome Standards protocol, using when needed an anaerobic generator. Self-collection samples will be preserved in stabilizing solution at room temperature and handed to the biologic laboratory within 24 hours to 7 days after collection. All samples will be homogenized and aliquoted to 200 mg subsamples that will be kept at -80ºC until the analysis. 16sRNA analysis. 16srRNA microbiota analysis will be performed using Multitag sequencing on an Ion Torrent personal genome machine with the objective of determining the microbial taxa that differentiates between patients who develop HE after TIPS placement. Stool DNA will be extracted and will be analyzed using published multitagged pyrosequencing (MTPA) techniques. Microbiota results will be analyzed using Metastats, standard nonparametric tests (Kruskal-Wallis test) and UNIFRAC QIIME (Quantitative Insights Into Microbial Ecology) principle component analyses (PCA) with multiple comparison adjustments. Functionality of microbiota will be assessed using PiCRUST (Phylogenetic Investigation of Communities by Reconstruction of Unobserved States), and results will be compared between groups. Linear discriminant analysis effect size (LEFSe) will be used to determine the taxa that differentiate the groups. Microbial taxa significantly different on LEFSe between the groups will be then introduced into a logistic regression model with clinical variables of defining cognitive impairment. To interrogate the specific taxa at a deeper level, bacterial families that emerge as significant in the prediction of the logistic regression models will be further analyzed at the genus levels to determine the specific genera associated with specific cognitive impairment or with normal cognitive function..
  • Neuropsychological function and cognitive reserve will be measured at baseline. At the 4 weeks and 6 months follow-up visit, only neuropsychological function will be assessed.

Tests specifically designed for Minimal HE evaluation: PHES ; EncephalApp Stroop; Critical Flicker frequency threshold; Animal naming test

Other cognitive function tests: Montreal Cognitive Assessment is a screening tool to distinguish patients with mild cognitive impairment from normal population. Digits-span of WAIS-IV evaluates attention and working memory. Vocabulary of WAIS-IV estimates premorbid IQ. Controlled Oral Word Association Test measures verbal fluency and executive function. ROCF assess visuo-constructional abilities and visual memory functions. Rey Auditory Verbal Learning Test evaluates auditory-verbal memory. Wisconsin Card Sorting Test to measure flexibility, categorization and abstract reasoning. Cuestionario Reserva Cognitiva to estimate the CR.

Being tested
Lifestyle intervention
Keywords
Transjugular intrahepatic portosystemic shunt (TIPS), sarcopenia, microbioma, physical therapy, nutrition, hepatic encephalopathy
Medical subject headings
Liver Cirrhosis, Hepatic Encephalopathy, Sarcopenia

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Lifestyle interventionBehavioural

    Resistance training and nutritional counseling

Study groups in NCT05346029
Study groupRoleWhat they receive
Standard of careNo interventionPatients will be followed-up according to standard clinical practices
Lifestyle interventionExperimentalPatients will undergo a 12 week lifestyle intervention (physical therapy and nutritional assessment)
Receives: Behavioral: Lifestyle intervention

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Development of post-TIPS overt HE within 6 months after TIPS placement

    Overt HE will be defined if any grade from 2 to 4 of West Haven Criteria are present: grade 2, fatigue, apathy, flapping tremor, ataxia, slurred speech; grade 3, somnolence, marked disorientation, rigor, stupor; grade 4, coma.

    Measured: 6 months

Secondary outcomes (11)
  1. 6 months mortality;

    Death

    Measured: 6 months

  2. development of a second episode of overt HE within the first 6 month

    Overt Hepatic encefphalopathy

    Measured: 6 months

  3. development of minimal HE within the first 6 months

    minimal HE detected through PHES neuropsicological test

    Measured: 6 months

  4. development of minimal HE within the first 6 months

    minimal HE detected through Encephal App Stroop neuropsicological tests

    Measured: 6 months

  5. development of minimal HE within the first 6 months

    minimal HE detected through Critical Flicker frequency threshold neuropsicological test

    Measured: 6 months

  6. development of minimal HE within the first 6 months

    minimal HE detected through Animal naming neuropsicological test

    Measured: 6 months

  7. time to development of either overt or minimal HE

    time to development of either overt or minimal HE

    Measured: 6 months

  8. development of portal hypertension complications during follow-up;

    ascites, variceal bleeding

    Measured: 6 months

  9. effects on sarcopenia

    transversal psoas measurement. Measurements will be performed at the level of the umbilicus. Axial psoas muscle thickness and transversal psoas muscle thickness will be measured. All measurements will be performed on the right psoas muscle. Psoas muscle thickness will be normalized by dividing the value by patient's height. Based on data published by Golse et al in 2017, sarcopenia is defined as a TPMT below 1562 mm/m for men and below 1464 mm/m for women

    Measured: 6 months

  10. need of admission

    hospital admission because of any cause

    Measured: 6 months

  11. percentage of follow-up days spent in the hospital

    percentage of follow-up days spent in the hospital

    Measured: 6 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted26 Apr 2022
  2. Study start1 Jan 2022
  3. Primary completion31 Dec 2024 (estimated)
  4. Study completion31 Dec 2025 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Prevention
Allocation
Randomised
Intervention model
Parallel groups
Model description
Participants are randomly assigned to standard medical care or to intervention group for the duration of the study
Masking
None (open label)
Enrolment
140 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT05346029
Sponsor's protocol ID
PI21/00131
Status last verified
Oct 2023
First submitted
11 Apr 2022
Last updated
10 Oct 2023
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Publications

  • Goldbecker A, Weissenborn K, Hamidi Shahrezaei G, Afshar K, Rumke S, Barg-Hock H, Strassburg CP, Hecker H, Tryc AB. Comparison of the most favoured methods for the diagnosis of hepatic encephalopathy in liver transplantation candidates. Gut. 2013 Oct;62(10):1497-504. doi: 10.1136/gutjnl-2012-303262. Epub 2013 Jan 7.

    PubMed 23297006
  • Lauridsen MM, Jepsen P, Vilstrup H. Critical flicker frequency and continuous reaction times for the diagnosis of minimal hepatic encephalopathy: a comparative study of 154 patients with liver disease. Metab Brain Dis. 2011 Jun;26(2):135-9. doi: 10.1007/s11011-011-9242-1. Epub 2011 Apr 12.

    PubMed 21484318
  • Riggio O, Merlli M, Pedretti G, Servi R, Meddi P, Lionetti R, Rossi P, Bezzi M, Salvatori F, Ugolotti U, Fiaccadori F, Capocaccia L. Hepatic encephalopathy after transjugular intrahepatic portosystemic shunt. Incidence and risk factors. Dig Dis Sci. 1996 Mar;41(3):578-84. doi: 10.1007/BF02282344.

    PubMed 8617139
  • Nardelli S, Lattanzi B, Torrisi S, Greco F, Farcomeni A, Gioia S, Merli M, Riggio O. Sarcopenia Is Risk Factor for Development of Hepatic Encephalopathy After Transjugular Intrahepatic Portosystemic Shunt Placement. Clin Gastroenterol Hepatol. 2017 Jun;15(6):934-936. doi: 10.1016/j.cgh.2016.10.028. Epub 2016 Nov 2.

    PubMed 27816756
  • Merli M, Giusto M, Lucidi C, Giannelli V, Pentassuglio I, Di Gregorio V, Lattanzi B, Riggio O. Muscle depletion increases the risk of overt and minimal hepatic encephalopathy: results of a prospective study. Metab Brain Dis. 2013 Jun;28(2):281-4. doi: 10.1007/s11011-012-9365-z. Epub 2012 Dec 7.

    PubMed 23224378
  • Gioia S, Merli M, Nardelli S, Lattanzi B, Pitocchi F, Ridola L, Riggio O. The modification of quantity and quality of muscle mass improves the cognitive impairment after TIPS. Liver Int. 2019 May;39(5):871-877. doi: 10.1111/liv.14050. Epub 2019 Feb 6.

    PubMed 30667572
  • Aamann L, Dam G, Borre M, Drljevic-Nielsen A, Overgaard K, Andersen H, Vilstrup H, Aagaard NK. Resistance Training Increases Muscle Strength and Muscle Size in Patients With Liver Cirrhosis. Clin Gastroenterol Hepatol. 2020 May;18(5):1179-1187.e6. doi: 10.1016/j.cgh.2019.07.058. Epub 2019 Aug 5.

    PubMed 31394282
  • Bajaj JS, Betrapally NS, Gillevet PM. Decompensated cirrhosis and microbiome interpretation. Nature. 2015 Sep 17;525(7569):E1-2. doi: 10.1038/nature14851. No abstract available.

    PubMed 26381988

Questions about this trial

What is this clinical trial studying?

A study testing Lifestyle intervention in people with Cirrhosis, Liver and Hepatic Encephalopathy, run by Anna Baiges at 3 sites in Spain.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 10 Oct 2023. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 3 sites in Spain. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Anna Baiges, MD, PhD (93 227 54 00 ext. 2824, abaigesa@clinic.cat), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Development of post-TIPS overt HE within 6 months after TIPS placement (time frame: 6 months). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT05346029, which also lists 8 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 10 Oct 2023.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in